Biogen Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher A. Viehbacher
- Full Time Employees
- 7,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 225 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Sep 17, 1991
- CIK
- 0000875045
- Website
- biogen.com
- Similar Companies
- Business
- Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.
Company News
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease
Canada Pension Plan Investment Board Makes New Investment in Biogen Inc. $BIIB
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
Bank of Nova Scotia Buys Shares of 16,446 Biogen Inc. $BIIB
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
Allworth Financial LP Takes $1.74 Million Position in Biogen Inc. $BIIB
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
15,985,736 Shares in Biogen Inc. $BIIB Bought by BlackRock Inc.
Biogen Completes Acquisition of RayThera Inc.
Biogen Inc. $BIIB Shares Acquired by Amundi
Why Biogen Stock Topped the Market Today
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Q2 Earnings Season in Full Swing
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised